BR9712683A - Agente de diagnóstico e/ou terapeuticamente ativo alvejável, formulação combinada, processo para preparação e uso do mesmo, formulação combinada, e processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente. - Google Patents

Agente de diagnóstico e/ou terapeuticamente ativo alvejável, formulação combinada, processo para preparação e uso do mesmo, formulação combinada, e processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente.

Info

Publication number
BR9712683A
BR9712683A BR9712683-7A BR9712683A BR9712683A BR 9712683 A BR9712683 A BR 9712683A BR 9712683 A BR9712683 A BR 9712683A BR 9712683 A BR9712683 A BR 9712683A
Authority
BR
Brazil
Prior art keywords
agent
combined formulation
human
diagnostic
processes
Prior art date
Application number
BR9712683-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Jo Klaveness
Pol Rongved
Anders Hogset
Helge Tolleshaug
Anne Navestad
Halldis Hellebust
Lars Hoff
Alan Cuthbertson
Dagfinn Lovhaug
Magne Solbakken
Original Assignee
Nyomed Imaging A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9622366.4A external-priority patent/GB9622366D0/en
Priority claimed from GBGB9622368.0A external-priority patent/GB9622368D0/en
Priority claimed from GBGB9622367.2A external-priority patent/GB9622367D0/en
Priority claimed from GBGB9700699.3A external-priority patent/GB9700699D0/en
Priority claimed from GBGB9708265.5A external-priority patent/GB9708265D0/en
Priority claimed from GBGB9711842.6A external-priority patent/GB9711842D0/en
Priority claimed from GBGB9711846.7A external-priority patent/GB9711846D0/en
Application filed by Nyomed Imaging A S filed Critical Nyomed Imaging A S
Priority claimed from PCT/GB1997/002954 external-priority patent/WO1998018501A2/en
Publication of BR9712683A publication Critical patent/BR9712683A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
    • Y10S977/929—Ultrasound contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Acoustics & Sound (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9712683-7A 1996-10-28 1997-10-28 Agente de diagnóstico e/ou terapeuticamente ativo alvejável, formulação combinada, processo para preparação e uso do mesmo, formulação combinada, e processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente. BR9712683A (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9622366.4A GB9622366D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GBGB9622368.0A GB9622368D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GBGB9622367.2A GB9622367D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GBGB9700699.3A GB9700699D0 (en) 1997-01-15 1997-01-15 Improvements in or relating to diagnostic/therapeutic agents
GBGB9708265.5A GB9708265D0 (en) 1997-04-24 1997-04-24 Contrast agents
GBGB9711842.6A GB9711842D0 (en) 1997-06-06 1997-06-06 Improvements in or relating to diagnostic/therapeutic agents
GBGB9711846.7A GB9711846D0 (en) 1997-06-06 1997-06-06 Improvements in or relating to diagnostic/therapeutic agents
PCT/GB1997/002954 WO1998018501A2 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents

Publications (1)

Publication Number Publication Date
BR9712683A true BR9712683A (pt) 1999-10-19

Family

ID=27562937

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712683-7A BR9712683A (pt) 1996-10-28 1997-10-28 Agente de diagnóstico e/ou terapeuticamente ativo alvejável, formulação combinada, processo para preparação e uso do mesmo, formulação combinada, e processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente.

Country Status (14)

Country Link
US (1) US6264917B1 (https=)
JP (1) JP2001503407A (https=)
KR (1) KR20000052829A (https=)
CN (2) CN1234742A (https=)
AT (1) ATE318618T1 (https=)
AU (1) AU733495B2 (https=)
BG (1) BG103438A (https=)
BR (1) BR9712683A (https=)
CA (1) CA2270120A1 (https=)
CZ (1) CZ149499A3 (https=)
DE (1) DE69735354T2 (https=)
IL (1) IL129444A0 (https=)
NO (1) NO991889L (https=)
NZ (1) NZ335596A (https=)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7637948B2 (en) 1997-10-10 2009-12-29 Senorx, Inc. Tissue marking implant
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US6524553B2 (en) * 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
EP1073716B1 (en) * 1998-04-28 2004-04-28 Amersham Health AS Improvements in or relating to separation processes
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
US6361774B1 (en) * 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US20090030309A1 (en) 2007-07-26 2009-01-29 Senorx, Inc. Deployment of polysaccharide markers
US6862470B2 (en) * 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US6725083B1 (en) 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
GB9912356D0 (en) * 1999-05-26 1999-07-28 Btg Int Ltd Generation of microfoam
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
AU2001266696A1 (en) 2000-06-02 2001-12-11 Bracco Research Usa Compounds for targeting endothelial cells
US8263739B2 (en) * 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US6514221B2 (en) * 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
CA2446993C (en) 2000-11-20 2009-06-02 Senorx, Inc. Tissue site markers for in vivo imaging
EP1424067B1 (en) * 2001-08-08 2010-06-02 Maria Antonia Garcia-Olmedo Dominguez Injectable foam and novel pharmaceutical applications thereof
US7198945B2 (en) * 2001-08-09 2007-04-03 Teruyuki Nagamune Cell having modified cell membrane
JP4493899B2 (ja) * 2001-08-09 2010-06-30 輝行 長棟 細胞膜が修飾された細胞
US7087212B2 (en) * 2001-08-17 2006-08-08 Mallinckrodt, Inc Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
US20030091633A1 (en) * 2001-11-15 2003-05-15 John Kelly Methods and compositions for use of (S)-bisoprolol
US20030118652A1 (en) * 2001-11-15 2003-06-26 John Kelly Methods and compositions for use of (S)-bisoprolol
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US20050100963A1 (en) * 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
GB0211949D0 (en) * 2002-05-23 2002-07-03 Glaxo Group Ltd Novel compounds compositions and processes
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US7623908B2 (en) 2003-01-24 2009-11-24 The Board Of Trustees Of The University Of Illinois Nonlinear interferometric vibrational imaging
WO2004068405A2 (en) * 2003-01-25 2004-08-12 Oraevsky Alexander A High contrast optoacoustical imaging using nanoparticles
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
PT2949658T (pt) 2003-03-03 2018-10-18 Bracco Suisse Sa Péptidos que ligam especificamente o recetor de hgf (cmet) e utilizações dos mesmos
US20040258760A1 (en) * 2003-03-20 2004-12-23 Wheatley Margaret A. Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
US7198777B2 (en) * 2003-06-17 2007-04-03 The Board Of Trustees Of The University Of Illinois Optical contrast agents for optically modifying incident radiation
US7217410B2 (en) * 2003-06-17 2007-05-15 The Board Of Trustees Of The Universtiy Of Illinois Surface modified protein microparticles
EP1667972B1 (en) 2003-09-10 2013-06-19 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
IL158658A0 (en) * 2003-10-29 2004-05-12 Moshe Schwarzberg Prokinetic drugs assistance to small intestine imaging
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
JP2007515471A (ja) * 2003-12-22 2007-06-14 ブラッコ・リサーチ・ソシエテ・アノニム 造影イメージング用の活性成分を有する気体封入マイクロベシクルのアセンブリー
US20050153371A1 (en) * 2004-01-07 2005-07-14 Ambit Biosciences Corporation Conjugated small molecules
US7610074B2 (en) * 2004-01-08 2009-10-27 The Board Of Trustees Of The University Of Illinois Multi-functional plasmon-resonant contrast agents for optical coherence tomography
ATE466596T1 (de) † 2004-01-20 2010-05-15 Sunnybrook & Womens College Hochfrequenz-ultraschall-darstellung mit kontrastmitteln
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
JP5710092B2 (ja) * 2004-09-24 2015-04-30 ユニヴァーシティ オヴ メリーランド、バルティモア 有機リン中毒を治療する方法
JP2006182673A (ja) * 2004-12-27 2006-07-13 Kenji Yamamoto マーカー付き医薬
US7586618B2 (en) * 2005-02-28 2009-09-08 The Board Of Trustees Of The University Of Illinois Distinguishing non-resonant four-wave-mixing noise in coherent stokes and anti-stokes Raman scattering
US7725169B2 (en) * 2005-04-15 2010-05-25 The Board Of Trustees Of The University Of Illinois Contrast enhanced spectroscopic optical coherence tomography
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
WO2006129099A1 (en) * 2005-06-02 2006-12-07 Cancercure Technology As Ultrasound treatment system
CN100402092C (zh) * 2005-06-07 2008-07-16 西安交通大学 血栓诊断和/或治疗用含气干粉活性剂及其制备工艺
US8052658B2 (en) 2005-10-07 2011-11-08 Bard Peripheral Vascular, Inc. Drug-eluting tissue marker
WO2007058895A2 (en) * 2005-11-11 2007-05-24 Visualsonics Inc. Overlay image contrast enhancement
WO2007090147A2 (en) 2006-01-31 2007-08-09 The Board Of Trustees Of The University Of Illinois Method and apparatus for measurement of optical properties in tissue
US8030376B2 (en) 2006-07-12 2011-10-04 Minusnine Technologies, Inc. Processes for dispersing substances and preparing composite materials
ATE469660T1 (de) * 2006-09-05 2010-06-15 Bracco Research Sa Gasgefüllte mikrovesikel mit polymer- modifizierten lipiden
US8064987B2 (en) 2006-10-23 2011-11-22 C. R. Bard, Inc. Breast marker
WO2008073965A2 (en) 2006-12-12 2008-06-19 C.R. Bard Inc. Multiple imaging mode tissue marker
US8401622B2 (en) 2006-12-18 2013-03-19 C. R. Bard, Inc. Biopsy marker with in situ-generated imaging properties
US20080241065A1 (en) * 2007-03-27 2008-10-02 Benaron David A Systems and methods for the detection and analysis of in vivo circulating cells, entities, and nanobots
US20090099062A1 (en) * 2007-05-31 2009-04-16 Ethan Lee Pyrvinium For The Treatment of Cancer
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
US8983580B2 (en) * 2008-01-18 2015-03-17 The Board Of Trustees Of The University Of Illinois Low-coherence interferometry and optical coherence tomography for image-guided surgical treatment of solid tumors
US7751057B2 (en) 2008-01-18 2010-07-06 The Board Of Trustees Of The University Of Illinois Magnetomotive optical coherence tomography
US8115934B2 (en) 2008-01-18 2012-02-14 The Board Of Trustees Of The University Of Illinois Device and method for imaging the ear using optical coherence tomography
US8311610B2 (en) 2008-01-31 2012-11-13 C. R. Bard, Inc. Biopsy tissue marker
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
US8670818B2 (en) 2008-12-30 2014-03-11 C. R. Bard, Inc. Marker delivery device for tissue marker placement
EP2345732A1 (en) 2010-01-19 2011-07-20 Universite Paris Descartes Methods for intracellular delivery of nucleic acids
BR112013002945A2 (pt) 2010-08-09 2016-06-07 Inst Nat Sante Rech Med composição farmacâutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse para uso em um método para tratamento de uma doença ocular em um sujeito
WO2012136813A2 (en) 2011-04-07 2012-10-11 Universitetet I Oslo Agents for medical radar diagnosis
US20130072854A1 (en) * 2011-09-19 2013-03-21 General Electric Company Microbubble complexes and methods of use
JP2012246306A (ja) * 2012-08-22 2012-12-13 Btg Internatl Ltd 注射可能な泡製剤および新規な医薬的適用
WO2014065513A1 (ko) * 2012-10-25 2014-05-01 서강대학교 산학협력단 약물을 함유한 나노입자가 결합된 초음파 조영제 및 이의 제조방법
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
CN104324005A (zh) * 2014-10-09 2015-02-04 唐春林 一种争光霉素脂质微泡及其制备方法
CN104382854A (zh) * 2014-10-09 2015-03-04 唐春林 一种多柔比星脂质微泡及其制备方法
CN104382904B (zh) * 2014-10-09 2018-02-13 唐春林 一种长春新碱脂质微泡及其制备方法
US11291931B2 (en) 2014-12-15 2022-04-05 Akadeum Life Sciences, Inc. Method and system for buoyant separation
US10662146B2 (en) 2015-09-15 2020-05-26 Praxis Bioresearch, LLC Prodrugs of fencamfamine
CN105727320B (zh) * 2016-01-30 2018-10-19 山西大学 检测小细胞肺癌的靶向纳米微泡及其制备方法和应用
WO2018112262A2 (en) 2016-12-16 2018-06-21 Diagnologix, Llc Buoyancy enabled separation method and system
CN106902362B (zh) * 2017-02-13 2018-04-13 牡丹江医学院 一种用于超声引导的麻醉药物制剂及其制备方法
US11090393B2 (en) * 2018-01-05 2021-08-17 Johnson & Johnson Consumer Inc. Mild surfactant preparation and method therefor
EP3773500A4 (en) * 2018-03-29 2022-03-16 Microvascular Therapeutics LLC COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE
WO2020014273A1 (en) 2018-07-09 2020-01-16 Akadeum Life Sciences, Inc. System and method for buoyant particle processing
CN110772275B (zh) * 2019-11-05 2023-08-15 上海联影医疗科技股份有限公司 一种基于超声的ct扫描方法、装置和系统
CN112374972B (zh) * 2020-09-18 2023-03-14 赛纳生物科技(北京)有限公司 一种生物化学芯片油封液
CN112314509B (zh) * 2020-12-17 2024-05-28 中国科学院深海科学与工程研究所 深海宏生物保真培养装置及培养方法
CN112641760B (zh) * 2021-01-08 2022-04-26 东南大学 二茂铁-黄连素/吲哚美辛@葡萄糖氧化酶@透明质酸纳米药物、制备方法与应用
CN113267629B (zh) * 2021-05-13 2022-06-24 广东优尼德生物科技有限公司 一种抗核抗体谱检测试剂盒及其制备方法
EP4392158A4 (en) 2021-08-26 2025-09-03 Akadeum Life Sciences Inc METHOD AND SYSTEM FOR FLOATING SEPARATION
US12196754B2 (en) 2022-04-01 2025-01-14 Akadeum Life Sciences, Inc. Method and system for buoyant-particle-assisted cell therapy
US20250213695A1 (en) * 2022-04-14 2025-07-03 Cedars-Sinai Medical Center Ultrasound-mediated gene therapy for deep vein thrombosis and post-thrombotic syndrome
CN114766645A (zh) * 2022-05-24 2022-07-22 四川大学 低盐芽菜的发酵方法
JP2026511329A (ja) 2023-02-14 2026-04-14 アカデューム ライフ サイエンセズ，インコーポレイテッド 部分的または完全に自動化された浮力補助分離方法およびシステム

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927916A (en) 1984-04-23 1990-05-22 The General Hospital Corporation Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
US5198424A (en) 1989-03-08 1993-03-30 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
IN172208B (https=) 1990-04-02 1993-05-01 Sint Sa
US5632986A (en) 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
WO1993020802A1 (en) 1992-04-09 1993-10-28 Northwestern University Acoustically reflective liposomes and methods to make and use the same
DE4232755A1 (de) 1992-09-26 1994-03-31 Schering Ag Mikropartikelpräparationen aus biologisch abbaubaren Mischpolymeren
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5534241A (en) 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
EP0712421A1 (en) 1993-07-23 1996-05-22 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
ES2152990T3 (es) 1993-09-09 2001-02-16 Schering Ag Principios activos y microparticulas que contienen gases.
US5716594A (en) 1994-06-06 1998-02-10 The Jmde Trust Biotin compounds for targetting tumors and sites of infection
EP0727225A3 (en) 1995-02-14 1997-01-15 Sonus Pharma Inc Compositions and methods for directed ultrasonic imaging
WO1996039149A1 (en) 1995-06-06 1996-12-12 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
CA2218541A1 (en) 1995-06-07 1996-12-19 Imarx Pharmaceutical Corp. Novel targeted compositions for diagnostic and therapeutic use
AU6378096A (en) 1995-06-07 1996-12-30 Brown University Research Foundation Spray dried polymeric microparticles containing imaging agen ts
US5690907A (en) 1995-06-08 1997-11-25 The Jewish Hospital Of St. Louis Avidin-biotin conjugated emulsions as a site specific binding system
US5780010A (en) 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US5910300A (en) 1995-11-01 1999-06-08 Bracco Research S.A. Amphiphilic linkers for coupling administrable diagnostically or physiologically active agents and bioselective targeting compounds
DE19549240A1 (de) 1995-12-21 1997-07-10 Schering Ag Tragbares Gerät zur Simulation von Ultraschalluntersuchungen
ATE248511T1 (de) 1996-03-12 2003-09-15 Univ Nebraska Zusammensetzung zur zielortspezifischen verabreichung eines medikamentes und verfahren zur anwendung
AU717020B2 (en) 1996-05-03 2000-03-16 Immunomedics Inc. Targeted combination immunotherapy of cancer
US5849727A (en) 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
DE19626530A1 (de) 1996-07-02 1998-01-15 Byk Gulden Lomberg Chem Fab MR-Kontrastmittelzubereitungen
WO1998004293A1 (en) 1996-07-31 1998-02-05 Immunomedics, Inc. Improved detection and therapy of lesions with biotin-chelate conjugates
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
JP2001505194A (ja) 1996-11-05 2001-04-17 ブリストル―マイヤーズ・スクイブ・カンパニー 分枝ペプチド・リンカー
DE19648664A1 (de) 1996-11-14 1998-05-28 Schering Ag Wirkstoffhaltige Mikropartikel, diese enthaltende Mittel, deren Verwendung zur ultraschallgesteuerten Freisetzung von Wirkstoffen sowie Verfahren zu deren Herstellung
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures

Also Published As

Publication number Publication date
NO991889L (no) 1999-06-28
BG103438A (bg) 2000-01-31
AU4786697A (en) 1998-05-22
KR20000052829A (ko) 2000-08-25
CA2270120A1 (en) 1998-05-07
DE69735354D1 (de) 2006-04-27
US6264917B1 (en) 2001-07-24
NO991889D0 (no) 1999-04-21
NZ335596A (en) 2000-10-27
ATE318618T1 (de) 2006-03-15
CN1234742A (zh) 1999-11-10
CZ149499A3 (cs) 1999-09-15
AU733495B2 (en) 2001-05-17
DE69735354T2 (de) 2006-11-30
JP2001503407A (ja) 2001-03-13
CN1440816A (zh) 2003-09-10
IL129444A0 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
BR9712683A (pt) Agente de diagnóstico e/ou terapeuticamente ativo alvejável, formulação combinada, processo para preparação e uso do mesmo, formulação combinada, e processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente.
BR9713978A (pt) Agente diagnóstico alvejável e/ou terapeuticamente ativo, processo para preparação e uso do mesmo, formulação combinada, e, processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente
GB9200387D0 (en) Improvements in or relating to contrast agents
BR0000409A (pt) Composição anidra para descoloração de fibras queratìnicas, utilização da composição anidra descolorante, processo de descoloração de fibras queratìnicas e dispositivo com vários compartimentos
ATE92931T1 (de) Fluor- und phosphorhaltige amphiphilische molekuele mit oberflaechenaktiven eigenschaften.
IT1256248B (it) Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x
BR0000419A (pt) Composição anidra para descoloração de fibras queratìnicas, utilização da composição anidra descolorante, processo de descoloração de fibras queratìnicas e dispositivo com vários compartimentos
WO1998048838B1 (en) Compounds
ATE224745T1 (de) Spritze und injektor mit magnetischer rührvorrichtung
MY113895A (en) Gel of an apolar medium, its use for the preparation of water-based drilling fluids
WO1998038486A3 (en) Ultrasonic probe, system and method for two-dimensional imaging or dimensional reconstruction
ATE367829T1 (de) Verbesserungen in oder bezüglich zu diagnostische/therapeutische mittel
BR9909636A (pt) Processo para a preparação de uma formulação, e, formulação
BR9406199A (pt) Agente de contraste uso do mesmo suspensões e concentrados não-aquosos formas formuladas a partir de um agente de contraste e processos para a preparação de um agente de contraste e para geração de imagens melhoradas de um corpo de animal humano ou não-humano
AR007282A1 (es) Metodo para obtener una imagen de una parte de un paciente y su uso
BR0015538A (pt) Emprego de polissiloxanos com grupos amino quaternários como coadjuvantes de formulação, e agentes contendo-os
NO308510B1 (no) Anvendelse av mikrokapsler for fremstilling av et ultralydkontrastmiddel for kontrastering ved fargedopplersonografi
ES2102920T3 (es) Composicion de teñido por oxidacion de las fibras queratinicas y procedimiento de teñido que utiliza esta composicion.
BR9907231A (pt) Composição pronta para o uso para tintura por oxidação das fibras queratìnicas, processo de tintura das fibras queratìnicas e dispositivo com vários comportamentos
EP0904803A3 (de) Vorrichtung zur kohärenten Verstärkung elektromagnetischer Schwingungen
PT853476E (pt) Preparacao farmaceutica que contem nimesulide para uso topico
BG99997A (bg) Подобрения,отнасящи се до контрастни агенти
ES2135476T3 (es) Utilizacion de remacemida para el tratamiento de la enfermedad de parkinson.
RU93006912A (ru) Способ экспресс-диагностики патологии внутренних органов
BR9904528A (pt) Sistema de liberação de um ativo sobre a pele, utilização do sistema de liberação de ativo e processo de tratamento cosmético

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: AMERSHAM HEALTH AS (NO)

Free format text: ALTERADO DE: NYCOMED IMAGING A/S

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 6A E 7A ANUIDADES.

B15K Others concerning applications: alteration of classification

Ipc: A61K 51/12 (2006.01), A61K 47/54 (2017.0